Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis (2024)

Abstract

Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.

Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.

Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).

Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.

Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

Original languageEnglish
Article number5463451
Number of pages6
JournalMultiple Sclerosis International
Volume2020
DOIs
Publication statusPublished - 2020

Access to Document

  • 5463451Final published version, 615 KB

    Fingerprint

    Dive into the research topics of 'Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis'. Together they form a unique fingerprint.

    View full fingerprint

    Cite this

    • APA
    • Author
    • BIBTEX
    • Harvard
    • Standard
    • RIS
    • Vancouver

    Daniels, K., van der Nat, P. B., Frequin, S. T. F. M., van der Wees, P. J., Biesma, D. H., Hoogervorst, E. L. J. (2020). Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. Multiple Sclerosis International, 2020, Article 5463451. https://doi.org/10.1155/2020/5463451

    Daniels, K ; van der Nat, P B ; Frequin, S T F M et al. / Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. In: Multiple Sclerosis International. 2020 ; Vol. 2020.

    @article{f687cebb4ebb4069a719488f54706404,

    title = "Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis",

    abstract = "Background: Recently, ocrelizumab (Ocrevus{\textregistered}) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.",

    author = "K Daniels and {van der Nat}, {P B} and Frequin, {S T F M} and {van der Wees}, {P J} and Biesma, {D H} and Hoogervorst, {E L J} and {van de Garde}, {E M W}",

    note = "Copyright {\textcopyright} 2020 K. Daniels et al.",

    year = "2020",

    doi = "10.1155/2020/5463451",

    language = "English",

    volume = "2020",

    journal = "Multiple Sclerosis International",

    issn = "2090-2654",

    publisher = "Hindawi Publishing Corporation",

    }

    Daniels, K, van der Nat, PB, Frequin, STFM, van der Wees, PJ, Biesma, DH, Hoogervorst, ELJ 2020, 'Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis', Multiple Sclerosis International, vol. 2020, 5463451. https://doi.org/10.1155/2020/5463451

    Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. / Daniels, K; van der Nat, P B; Frequin, S T F M et al.
    In: Multiple Sclerosis International, Vol. 2020, 5463451, 2020.

    Research output: Contribution to journalArticleAcademicpeer-review

    TY - JOUR

    T1 - Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis

    AU - Daniels, K

    AU - van der Nat, P B

    AU - Frequin, S T F M

    AU - van der Wees, P J

    AU - Biesma, D H

    AU - Hoogervorst, E L J

    AU - van de Garde, E M W

    N1 - Copyright © 2020 K. Daniels et al.

    PY - 2020

    Y1 - 2020

    N2 - Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

    AB - Background: Recently, ocrelizumab (Ocrevus®) was approved for the treatment of primary progressive multiple sclerosis (PPMS) based on data from the ORATORIO clinical trial. Real-world data about the clinical effectiveness of ocrelizumab has yet to be gathered.Objective: The aim of this study was to provide data about the clinical effectiveness of ocrelizumab for patients diagnosed with PPMS in a real-world setting.Methods: We conducted a retrospective cohort study of all patients with PPMS who started ocrelizumab treatment (n = 21) in St. Antonius Hospital (Utrecht/Nieuwegein, the Netherlands) between April 2018 and December 31, 2018. Primary outcome was pre- versus post-ocrelizumab disability worsening rate (from 96 weeks prior to first ocrelizumab administration up to 24 weeks post first ocrelizumab administration).Results: Disability worsening rate while on treatment significantly differed (lower) from disability worsening rate in pre-treatment period (Z = -2.81, p ≤ .01). Three out of 17 patients showed a clinically relevant improvement in disability status after treatment start.Conclusion: Ocrelizumab can stabilize disability progression in patients with PPMS. Some patients even showed a clinically relevant improvement in disability status. Further research should help to identify which patients benefit most from ocrelizumab.

    U2 - 10.1155/2020/5463451

    DO - 10.1155/2020/5463451

    M3 - Article

    C2 - 32607256

    SN - 2090-2654

    VL - 2020

    JO - Multiple Sclerosis International

    JF - Multiple Sclerosis International

    M1 - 5463451

    ER -

    Daniels K, van der Nat PB, Frequin STFM, van der Wees PJ, Biesma DH, Hoogervorst ELJ et al. Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis. Multiple Sclerosis International. 2020;2020:5463451. doi: 10.1155/2020/5463451

    Real-World Results of Ocrelizumab Treatment for Primary Progressive Multiple Sclerosis (2024)
    Top Articles
    Latest Posts
    Article information

    Author: Aracelis Kilback

    Last Updated:

    Views: 6302

    Rating: 4.3 / 5 (64 voted)

    Reviews: 95% of readers found this page helpful

    Author information

    Name: Aracelis Kilback

    Birthday: 1994-11-22

    Address: Apt. 895 30151 Green Plain, Lake Mariela, RI 98141

    Phone: +5992291857476

    Job: Legal Officer

    Hobby: LARPing, role-playing games, Slacklining, Reading, Inline skating, Brazilian jiu-jitsu, Dance

    Introduction: My name is Aracelis Kilback, I am a nice, gentle, agreeable, joyous, attractive, combative, gifted person who loves writing and wants to share my knowledge and understanding with you.